Phase I/II trial of intravenous Doxil® and whole abdomen hyperthermia in patients with refractory ovarian cancer

References

• Alvarez AA, Clarke-Pearson DL. Platinum-resistant ovarian cancer: second-line treatment options. American Journal of Cancer 2003;2:1–13.
   Google Scholar
• Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. Journal of Clinical Oncology 2001;19:3312–3322.
   PubMed Web of Science ®Google Scholar
• Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang U. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. Journal of Clinical Oncology 1997;15:987–993.
   Google Scholar
• Huang SK, Stauffer PR, Hong KU, Guo JWH, Phillips TL, Huang A, Papahadjopoulos D. Liposomes and hyperthermia in mice—increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Research 1994;54:2186–2191.
   Google Scholar
• Gaber MH, Wu NZ, Hong KU, Huang SK, Dewhirst MW, Papahadjopoulos D. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. International Journal of Radiation Oncology, Biology and Physics 1996;36:1177–1187.
   PubMed Web of Science ®Google Scholar
• Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Research 2000;60:4440–4445.
   Google Scholar
• Kong G, Dewhirst MW. Hyperthermia and liposomes. International Journal of Hyperthermia 1999;15: 345–370.
   PubMed Web of Science ®Google Scholar
• Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D, Dewhirst MW. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Research 2000;60:6950–6957.
   Google Scholar
• Ben-Yosef R, Gipps M, Zeira M. Hyperthermia and liposomal encapsulated doxorubicin. Israel Medical Association Journal 2003;5:407–409.
   PubMed Web of Science ®Google Scholar
• Maruyama K, Unezaki S, Takahashi N, Iwatsuru M. Enhanced delivery of doxorubicin to tumor by long-circulating thermosensitive liposomes and local hyperthermia. Biochimica et Biophysica Acta 1993;1149: 209–216.
   PubMed Web of Science ®Google Scholar
• Andersen A, Warren DJ, Slordal L. A sensitive and simple high-performance liquid-chromatographic method for the determination of doxorubicin and its metabolites in plasma. Therapy Drug Monitoring 1993;15: 455–461.
   Google Scholar
• Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R, Sharpington T. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. Journal of Clinical Oncology 2000;18:3093–3100.
   PubMed Web of Science ®Google Scholar
• Meyer T, Rustin GJS. Role of tumour markers in monitoring epithelial ovarian cancer. British Journal of Cancer 2000;82:1535–1538.
   PubMed Web of Science ®Google Scholar
• Rustin GJS, Nelstrop AE, Bentzen SM, Piccart MJ, Bertelsen K. Use of tumour markers in monitoring the course of ovarian cancer. Annals of Oncology 1999;10:21–27.
   Google Scholar
• Jones EL, Samulski TV, Dewhirst MW, Alvarez-Secord A, Berchuck A, Clarke-Pearson D, Havrilesky Soper J, Prosnitz LR. A pilot phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma. Cancer 2003;98:277–282.
   Google Scholar
• Gaber MH, Hong KU, Huang SK, Papahadjopoulos D. Thermosensitive sterically stabilized liposomes—formulation and in-vitro studies on mechanism of doxorubicin release by bovine serum and human plasma. Pharmaceutical Research 1995;12:1407–1416.
   PubMed Web of Science ®Google Scholar
• Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Research 2000;60:1197–1201.
   PubMed Web of Science ®Google Scholar
• Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Research 2001;61:3027–3032.
   Google Scholar
• Song CW. Effect of local hyperthermia on blood—flow and microenvironment—a review. Cancer Research 1984;44:4721–4730.
   Google Scholar
• Dewhirst MW, Prosnitz L, Thrall D, Prescott D, Clegg S, Charles C, MacFall J, Rosner G, Samulski T, Gillette E, Larue S. Hyperthermic treatment of malignant diseases: current status and a view toward the future. Seminars in Oncology 1997;24:616–625.
   Google Scholar
• Shinkai M, Suzuki M, Iijima S, Kobayashi T. Antibody-conjugated magnetoliposomes for targeting cancer-cells and their application in hyperthermia. Biotechnology and Applied Biochemistry 1995;21:125–137.
   PubMed Web of Science ®Google Scholar
• Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecology and Oncology 2000;78:369–372.
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis UA, Parker LM, Harris LN, Winer EP. Phase I study of Doxil and vinorelbine in metastatic breast cancer. Annals of Oncology 1999;10:1113–1116.
   PubMed Web of Science ®Google Scholar
• Hubert A, Lyass 0, Pode D, Gabizon A. Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anti-Cancer Drugs 2000;11: 123–127.
   Google Scholar
• Amantea MA, Forrest A, Northfelt DW, Mamelok R Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi'ss sarcoma. Clinical Pharmacology & Therapeutics 1997;61:301–311.
   PubMed Web of Science ®Google Scholar
• Lyass 0, Uziely B, Ben Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, Gabizon A. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000;89:1037–1047.
   Google Scholar
• Hahn CA, Jones EL, Blivin JL, Sanders LL, Yu D, Dewhirst MW, Secord AA, Prosnitz LR. Prospective assessment of quality of life in ovarian cancer patients receiving whole abdomen hyperthermia and liposomal doxorubicin. International Journal of Hyperthermia 2005;21:349–357.
   PubMed Web of Science ®Google Scholar